INTRODUCTION Leishmaniasis is classified into three clinical presentations: visceral, coetaneous and mucocutaneous. The latter is usually secondary to hematogenous spread after months or years of skin infection and can manifest as infiltrative lesions, ulcerated or vegetating in nose, pharynx, larynx and mouth, associated or not with ganglionics infarction. Laryngeal involvement is part of the ...

Serum IgE levels and the expression of low affinity receptor for IgE (Fc epsilon RII/CD23) are increased in cutaneous leishmaniasis. The ligation of CD23 receptor by IgE-anti-IgE immune complexes results in nitric oxide (NO) production, which is a critical leishmanicidal factor. Human monocytes/macrophages express Fc epsilon RII/CD23 after activation with IFN-gamma and IL-4. In the present stud...

BACKGROUND Leishmaniasis is an endemic disease in Iran. Although many treatments have been suggested for this disease, there hasn't been an effective and safe treatment yet. Regarding the healing effect of honey in the chronic ulcers and its reported therapeutic effect in cutaneous leishmaniasis, we performed a study to better evaluate the efficacy of honey in cutaneous leishmaniasis and its fi...

Vole bacillus vaccination has been used extensively in recent years in carefully selected groups and communities. For reasons stated in detail by Wells (1946), the great majority of the earlier trials were conducted and are being followed up in institutions for the mentally defective. These provide a comparatively static population, permitting not only long-term assessment of the capacity of th...

BACKGROUND/AIMS The diagnosis of cutaneous leishmaniasis (CL) is based on the microscopic detection of amastigote, isolation of the parasite, or the detection of Leishmania DNA. Nevertheless, since these techniques are time consuming and not usually available in many endemic countries, the diagnosis remains clinical. Consequently, such disease may be overlooked because of its similarity to othe...

Visceral leishmaniasis is a systemic infectious disease that can cause to a severe, potentially life-threatening chronic condition in humans. Risk factors for infection in urban areas have been associated with poor living conditions, the presence of sand fly vectors and infected pets. This study aimed to describe sand fly and canine infection in the neighborhoods of human visceral leishmaniasis...

Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin in dogs with leishmaniasis and dec...

Canine leishmaniasis is a chronic parasitic disease transmitted by small bloodsucking insects. Clinically, affected patients present with progressive wasting, slight or marked reduction in appetite, lymphadenomegaly, splenomegaly, and cutaneous lesions (e.g., dry desquamation [dry seborrhea], ulcers, nodules). A correct diagnosis is based on specific serologic and molecular tests and nonspecifi...

Visceral leishmaniasis is associated with chronic inflammatory stimulation, resulting in different clinical manifestations, ranging from unapparent infection to a systemic disease. In dogs, there are descriptions of neurological involvement with inflammatory infiltrates and specific antibodies in cerebrospinal fluid. To investigate the involvement of the choroid plexus and the blood-CSF barrier...